BIO warned that a proposed OMB rule governing federal financial assistance could destabilize the biomedical research ecosystem by shifting power away from peer review and adding at-will termination and suspension authority. BIO said the proposal would increase uncertainty and administrative burden, discouraging academic infrastructure investments and private-sector follow-on capital. The organization’s comments argue the rule could delay patient access to new medicines by weakening merit-based funding decisions and reducing the predictability needed for long-horizon therapeutic development. The filing arrives amid heightened sensitivity around grant oversight mechanics, with biotech stakeholders pressing for transparency and stability in funding frameworks that directly influence pipeline timing.